The companies announced the partnership in March to develop trastuzumab deruxtecan, for which they plan to file approval later this year based on the successful Phase II study.
Activist investor venBio had a good Friday. Seattle Genetics and Immunomedics did not. The two latter companies agreed to fold on their $2 billion oncology deal, while Immunomedics' CEO and CSO also forfeited their jobs.
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.